drugset / Trial / NCT00024180

FR901228 in Treating Patients With Hematologic Cancer

NCT00024180

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.

Timeline

Start
2002-01
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide 13 mg/m2 Intravenous

Indications